Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
RESEARCH TOOLSreports
Holding CTXR?
Track your performance easily
CTXR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.48 - $1.07
Previous Close$0.55
Volume743.15K
Average Volume (3M)2.18M
Market Cap
$101.21M
Enterprise Value$82.06M
Total Cash (Recent Filing)$17.91M
Total Debt (Recent Filing)$320.01K
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Feb 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding180,725,407
10 Day Avg. Volume732,482
30 Day Avg. Volume2,176,699
Standard Deviation0.30
R-Squared0.08
Alpha0.00820
Financial Highlights & Ratios
Price to Book (P/B)1.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.19
Forecast
1Y Price Target
$5.00Price Target Upside792.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Citius Pharmaceuticals News
Ownership Overview
6.82% Insiders
6.31% Mutual Funds
9.75% Other Institutional Investors
77.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.48 and its highest was $1.07 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Currently, no data Available
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is Feb 07, 2025 which is in 140 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Aug 12, 2024. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 180,725,400 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -11.594%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Among the largest hedge funds holding Citius Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Citius Pharmaceuticals’s shares valued at N/A.
---
Citius Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (792.86% Upside)
$5.00 (792.86% Upside)
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.35%
12-Months-Change
Fundamentals
Return on Equity
-41.76%
Trailing 12-Months
Asset Growth
-12.06%
Trailing 12-Months
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
---
CTXR Stock 12 Month Forecast
Average Price Target
$5.00
▲(792.86% Upside)
Technical Analysis
Aclaris Therapeutics
―
Cyclacel Pharmaceuticals
―
Palatin Technologies
―
Axsome Therapeutics
―
Best Analysts Covering CTXR
1 Year
1 Year Success Rate
10/25 ratings generated profit
1 Year Average Return
+3.40%
initiated a buy rating 2 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +3.40% per trade.
---